Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Hodgkin Disease 41Lymphoma 16Urinary Bladder Neoplasms 7Melanoma 6Prostatic Neoplasms 3Neoplasms 3Leukemia 3Glioma 3Carcinoma, Non-Small-Cell Lung 3Testicular Neoplasms 2Testicular Germ Cell Tumor 2Skin Neoplasms 2Lymphoma, Large-Cell, Anaplastic 2Central Nervous System Neoplasms 2Breast Neoplasms 2Brain Neoplasms 2Astrocytoma 2Urothelial Carcinoma of the Bladder 1Urethral Neoplasms 1Ureteral Neoplasms 1Teratoma 1Survival Without Progression 1Seminoma 1Rhabdoid Tumor 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Pathologic Complete Response 1Oligodendroglioma 1Neurofibromatosis 1 1

Interventions

durvalumab 1Vinblastine 1Methotrexate 1Gemcitabine 1Doxorubicin 1Cystectomy 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Bladder Adenocarcinoma × Vinblastine × Clear all
NCT03912818 2023-09-11

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Stanford University

Phase 2 Terminated
7 enrolled 9 charts
GenitourinarySarcoma

Bladder Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡